Trials
`Lovsin, James
`Berghoff, Paul; Suggs, James V.; docketing@mbhb.com; Rigel IPR Group; tfink@omm.com; jeng@kslaw.com;
`VYen@KSLAW.com; EDiamond@KSLAW.com; hsayeed@omm.com; jli@omm.com; bhaber@omm.com; Trials
`RE: IPR2022-01423 - Joint request to file a joint motion to dismiss and/or terminate the petition
`Monday, December 19, 2022 2:08:57 PM
`
`From:
`To:
`Cc:
`
`Subject:
`Date:
`
`Counsel,
`
`The parties are authorized to file a joint motion to terminate IPR2022-01423. The parties are
`reminded of their obligation under 37 C.F.R. § 42.74 to file a copy of the settlement agreement and
`any collateral agreements (including any licensing agreements) with the Board. In the motion, the
`parties should also include a statement that there are no other agreements, oral or written,
`between the parties made in connection with, or in contemplation of, the termination of the
`proceeding, assuming such a statement is correct. If the parties cannot make such a statement, the
`other agreement(s) should be filed pursuant to 37 C.F.R. § 42.74.
`
`The parties also are authorized to file a joint request to treat the settlement agreement as business
`confidential information. To have the settlement agreement treated as business confidential
`information under 37 C.F.R. § 42.74(c), the parties must file the confidential settlement agreement
`electronically in the Patent Trial and Appeal Case Tracking System (PTACS) as an exhibit in
`accordance with the instructions provided on the Board’s website (uploading as “Parties and Board
`Only”). The parties are directed to FAQ G2 on the Board’s website at
`https://www.uspto.gov/sites/default/files/documents/p-tacts_faqs_20221007.pdf for guidance on
`how to file their settlement agreement as confidential. Please submit the joint motion and joint
`request no later than January 16, 2023.
`
`Regards,
`
`Esther Goldschlager
`Supervisory Paralegal Specialist
`Patent Trial & Appeal Board
`U.S. Patent & Trademark Office
`(571) 272-7822
`
`From: Lovsin, James <Lovsin@mbhb.com>
`Sent: Sunday, December 18, 2022 2:35 PM
`To: Trials <Trials@USPTO.GOV>
`Cc: Berghoff, Paul <Berghoff@mbhb.com>; Suggs, James V. <suggs@mbhb.com>;
`docketing@mbhb.com; Rigel IPR Group <RigelIPR@mbhb.com>; tfink@omm.com; jeng@kslaw.com;
`VYen@KSLAW.com; EDiamond@KSLAW.com; hsayeed@omm.com; jli@omm.com;
`bhaber@omm.com
`Subject: IPR2022-01423 - Joint request to file a joint motion to dismiss and/or terminate the petition
`
`CAUTION: This email has originated from a source outside of USPTO. PLEASE CONSIDER THE SOURCE before
`responding, clicking on links, or opening attachments.
`
`Exhibit 3002
`
`

`

`
`Dear Honorable Board,
`
`The parties to IPR2022-01423 have reached a settlement that addresses this
`proceeding. Accordingly, Petitioner Rigel Pharmaceuticals, Inc. and Patent Owner
`Servier Pharmaceuticals LLC seek authorization to file a joint motion to dismiss
`and/or terminate the petition pursuant to 37 C.F.R. §§ 42.71(a) and 42.72. The
`parties can make themselves available for a conference call, should the Board find it
`helpful.
`
`Respectfully submitted,
`
`James Lovsin
`Counsel for Petitioner, Rigel Pharmaceuticals, Inc.
`
`
`
`
`